Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 4/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 14/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90926 | 0.90 | MAP2K4 (0.47) | MAP2K4GRIA2GRIA4CYP2C19MAP2K7 | |
| SCHEMBL91040 | 0.90 | MAPK11 (0.44) | MAP2K4GRIA2CYP2C19CYP1A2 | |
| SCHEMBL8594191 | 0.88 | KDM4E (0.45) | GRIA2GRIA4CYP2C19CYP1A2 | |
| SCHEMBL90932 | 0.86 | MAP2K4 (0.46) | MAP2K4MAP2K7 | |
| SCHEMBL90984 | 0.86 | MAP2K4 (0.43) | MAP2K4GRIA2GRIA4CYP2C19MAP2K7 | |
| SCHEMBL90865 | 0.80 | GRIA2 (0.47) | MAP2K4GRIA2GRIA4CYP2C19CYP1A2 | |
| SCHEMBL90956 | 0.79 | KDM4E (0.45) | MAP2K4GRIA2GRIA4CYP2C19MAP2K7 | |
| SCHEMBL90940 | 0.78 | GRIA2 (0.45) | MAP2K4GRIA2CYP2C19CYP1A2 | |
| SCHEMBL90929 | 0.78 | ATM (0.53) | MAP2K4GRIA2CYP1A2 | |
| SCHEMBL8595107 | 0.77 | GRIA2 (0.47) | MAP2K4GRIA2CYP2C19MAP2K7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MAP2K4 419/4885GRIA2 634/4885GRIA4 608/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MAP2K4 419/4885GRIA2 634/4885GRIA4 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.